Info

🌱 來自: Pharmacogenomics

Drug targets

  • 5,10-Methylenetetrahydrofolate reductase (MTHFR)
    • Involved in metabolism of
    • 5,10-methylenetetrahydrofolate to 5-methylenetetrahydrofolate,
      • methyl donor for the methylation of DNA,
      • homocysteine,
      • & DNA synthesis
  • Reduced MTHFR activity affects intracellular folate pools → ↑ tox in pts treated w/ antifolates
  • Thymidylate synthase (TS)
  • Essential enzyme in de novo synthesis of thymidylate, precursor of thymidine triphosphate, essential for DNA synthesis & repair
  • TS gene promoter is polymorphic & has 2 (TSER2) or 3 (TSER3) 28-bp tandem repeat sequences
  • In vitro studies show TS promoters w/ the TSER3 sequence generate 3× higher mRNA than those w/ the TSER2 sequence
  • Inhibition of TS by FdUMP is 1 of the 1° mechanisms of action of 5-FU
  • TS expression levels inversely correlate w/ the sensitivity of tumors to 5-FU; therefore, TSER2 homozygotes respond better to 5-FU than TSER3 homozygotes or heterozygotes (Devita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 10th ed. 2014; Annu Rev Med. 2015;66:65; Br J Haematol 2003;122(2):240)